Novartis Secukinumab Granted New Indication in China for Active Psoriatic Arthritis

On January 9, the official website of the National Medical Products Administration (NMPA) showed that Novartis' secukinumab received approval for a new indication to treat adult patients with active psoriatic arthritis. This is the third indication for secukinumab in China, following "moderate to severe plaque psoriasis" and "ankylosing spondylitis."

Secukinumab, as the world's first approved fully human interleukin (IL)-17A inhibitor, can specifically neutralize IL-17A from various sources and inhibit its pro-inflammatory effects. IL-17A is a hallmark cytokine involved in the inflammation and disease progression of psoriasis, psoriatic arthritis, and ankylosing spondylitis, playing a cornerstone role in the pathogenesis.

The FUTURE series studies and the MAXIMISE study have confirmed that secukinumab can rapidly and comprehensively improve disease activity across the six disease dimensions in patients with psoriatic arthritis, including peripheral arthritis, axial involvement, enthesitis, dactylitis, psoriasis, and nail psoriasis.The EXCEED study demonstrated that secukinumab is as effective as adalimumab for peripheral arthritis and more effective than adalimumab for psoriasis.

ULTIMATE Study CertificationSecukinumab Significantly Improves Synovitis and Enthesitis Assessed by Ultrasound at Week 12 in Patients with Psoriatic Arthritis, Showing Significant Differences from Placebo as Early as Week 1. FUTURE 5 Data Show that Nearly 90% of Psoriatic Arthritis Patients Treated with Secukinumab 300mg for Two Years Had No Radiographic Progression. Clinical Trial Results Over Five Years Indicate That Secukinumab is Effective, Durable, and Well-Tolerated in Patients with Psoriatic Arthritis.

Copyright © 2024 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

↑ Long pressScan the code, Schedule Live ↑